Cancer cells are often described as “glutamine addicted,” relying heavily on this amino acid to fuel growth. But new research reveals how some tumors sidestep this vulnerability.

Cancer remains one of the leading causes of morbidity and mortality worldwide, despite significant advances in molecular biology, targeted therapy, and ...

Antitumor activity was modest overall (ORR 12.1%), while ORR at the recommended phase 2 dose was 21.1% with only 5.3% primary progression versus 33.7% previously reported. Efficacy signals were ...

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...